高FGF23水平与骨质疏松患者骨小梁微结构受损相关
这项横断面研究纳入82例骨质疏松患者,检测C端FGF23水平与骨转换标志物,并用高分辨率外周定量CT测量桡骨远端和胫骨微结构。结果显示FGF23水平与骨小梁微结构呈显著负对数相关,与皮质骨无关;校正年龄、BMI、磷酸盐、骨特异性碱性磷酸酶、维生素D3和PTH后,FGF23仍是骨小梁参数降低的预测因子。作者指出高FGF23水平与骨小梁微结构受损相关,需未来纵向研究验证并探讨其与骨折风险的关系。
要点
- 在82例骨质疏松患者中,FGF23水平与桡骨远端和胫骨的骨小梁微结构呈显著负对数相关,与皮质骨微结构无关。
- 校正年龄、BMI、磷酸盐、骨特异性碱性磷酸酶、维生素D3和PTH后,FGF23仍为骨小梁参数降低的预测因子。
- 作者结论认为高FGF23水平与骨质疏松患者骨小梁微结构受损相关,需未来纵向研究验证并探讨其与骨折风险的关系。
核心结论
- 高FGF23水平与骨质疏松患者骨小梁微结构受损相关,该关联在校正包括磷酸盐和维生素D在内的混杂变量后似乎仍然存在。
- 未来需要纵向研究来验证这些发现,并探讨FGF23与骨折风险的关系。
研究设计与样本
- 横断面研究,纳入82例骨质疏松患者(腰椎或全髋DXA T值≤-2.5)。
- 检测C端FGF23水平及骨转换标志物,采用高分辨率外周定量CT(HR-pQCT)测量桡骨远端和胫骨微结构,使用相关和回归模型分析。
主要发现
- 在桡骨远端和胫骨两个部位,FGF23水平与骨小梁微结构均呈显著负对数相关,而与皮质骨微结构无显著相关。
- 使用多元线性回归模型,校正年龄、BMI、磷酸盐、骨特异性碱性磷酸酶、维生素D3和PTH后,FGF23仍为骨小梁参数降低的预测因子。
局限性
- 未来需要纵向研究来验证这些发现,并探讨FGF23与骨折风险的关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: This cross-sectional study examined the associations between c-terminal FGF23 levels, laboratory markers of bone metabolism and bone microarchitecture in 82 patients with osteoporosis. Higher FGF23 levels were associated with impaired trabecular but not cortical bone microarchitecture, and this was confirmed after adjusting for confounding variables such as age or BMI. INTRODUCTION: Fibroblast growth factor 23 (FGF23) is an endocrine hormone-regulating phosphate and vitamin D metabolism. While its mode of action is well understood in diseases such as hereditary forms of rickets or tumor-induced osteomalacia, the interpretation of FGF23 levels in patients with osteoporosis with regard to bone microarchitecture is less clear. METHODS: C-terminal FGF23 levels and bone turnover markers were assessed in 82 patients with osteoporosis (i.e., DXA T-score ≤ - 2.5 at the lumbar spine or total hip). Bone microarchitecture was measured by high-resolution peripheral quantitative computed tomography (HR-pQCT) at the distal radius and tibia. Data were analyzed in a cross-sectional design using correlation and regression models. RESULTS: We found a significant negative logarithmic correlation between FGF23 levels and trabecular but not cortical bone microarchitecture at both skeletal sites. Furthermore, using a multiple linear regression model, we confirmed FGF23 as a predictor for reduced trabecular parameters even when adjusting for confounding factors such as age, BMI, phosphate, bone-specific alkaline phosphatase, vitamin D3, and PTH. CONCLUSIONS: Taken together, high FGF23 levels are associated with impaired trabecular bone microarchitecture in osteoporosis patients, and this association seems to occur after adjustment of confounding variables including phosphate and vitamin D. Future longitudinal studies are now needed to validate our findings and investigate FGF23 in relation to fracture risk.
引用
- Rupp T, Butscheidt S, Vettorazzi E, et al. High FGF23 levels are associated with impaired trabecular bone microarchitecture in patients with osteoporosis. Osteoporos Int. 2019. PMID: 31044263. doi:10.1007/s00198-019-04996-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。